Laurent Levy, CEO of Nanobiotix. (Photo credits: Nanobiotix)
(AOF) – Nanobiotix (+43.90% to 6.72 euros) posted the largest increase in the SRD market after announcing the signing of a global licensing, co-development and marketing agreement with Janssen Pharmaceutica NV ( Janssen), for product candidate NBTXR3.
The biotech “pioneer of physics-based approaches to expand treatment possibilities for cancer patients” specifies that NBTXR3 is currently being evaluated in several studies covering different indications of solid tumors
Nanobiotix grants Janssen an exclusive license for the development and commercialization of NBTXR3. This license is worldwide with the exception of the territories already covered by the license agreement with LianBio, partner of Nanobiotix.
Nanobiotix will receive short-term financial and operational support worth up to $60 million. This sum includes an upfront payment of $30 million, as well as operational support for Nanoray-312 study development and regulatory activities of up to $30 million, which Janssen may provide at its sole discretion. .
Nanobiotix will retain operational control of Nanoray-312 and all other ongoing studies, as well as manufacturing of NBTXR3 and initial clinical and commercial supply.
Nanobiotix is eligible for milestone payments of up to $1.8 billion in total, tied to the achievement of development, regulatory and commercialization goals. The company will also receive double-digit tiered royalties on net sales of NBTXR3.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.